Aurora kinase inhibitors

JJEM (Jos) Kitzen; Maja de Jonge; Jaap Verweij

doi:10.1016/j.critrevonc.2009.03.009

Aurora kinase inhibitors

JJEM (Jos) Kitzen
, Maja de Jonge
, Jaap Verweij

Medical Oncology

External organisation

Research output: Contribution to journal › Article › Academic › peer-review

86 Citations (Scopus)

Abstract

Most human cancer cells are characterized by changes in the amount or organization of DNA resulting in chromosome instability and aneuploidy. Several mitotic kinases, Aurora kinases amongst others, regulate the progression of the cell through mitosis. So far three Aurora kinases have been identified in man: Aurora-A, Aurora-B and Aurora-C. Aurora kinases were recently identified as a potential target in anticancer therapy, and various Aurora-A and Aurora-B kinase inhibitors are in development. In this review we provide a brief insight into the mechanism of action as far as currently available. We review the available pre-clinical data, discuss the clinical phase I data and try to give a direction for future headings. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	99-110
Number of pages	12
Journal	Critical Reviews in Oncology/Hematology
Volume	73
Issue number	2
DOIs	https://doi.org/10.1016/j.critrevonc.2009.03.009
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-03-86-08

Access to Document

10.1016/j.critrevonc.2009.03.009

http://hdl.handle.net/1765/16086

Cite this

@article{298620cf56c44cadbac252e35472449f,

title = "Aurora kinase inhibitors",

abstract = "Most human cancer cells are characterized by changes in the amount or organization of DNA resulting in chromosome instability and aneuploidy. Several mitotic kinases, Aurora kinases amongst others, regulate the progression of the cell through mitosis. So far three Aurora kinases have been identified in man: Aurora-A, Aurora-B and Aurora-C. Aurora kinases were recently identified as a potential target in anticancer therapy, and various Aurora-A and Aurora-B kinase inhibitors are in development. In this review we provide a brief insight into the mechanism of action as far as currently available. We review the available pre-clinical data, discuss the clinical phase I data and try to give a direction for future headings. (C) 2009 Elsevier Ireland Ltd. All rights reserved.",

author = "Kitzen, \{JJEM (Jos)\} and \{de Jonge\}, Maja and Jaap Verweij",

year = "2010",

doi = "10.1016/j.critrevonc.2009.03.009",

language = "Undefined/Unknown",

volume = "73",

pages = "99--110",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Aurora kinase inhibitors

AU - Kitzen, JJEM (Jos)

AU - de Jonge, Maja

AU - Verweij, Jaap

PY - 2010

Y1 - 2010

N2 - Most human cancer cells are characterized by changes in the amount or organization of DNA resulting in chromosome instability and aneuploidy. Several mitotic kinases, Aurora kinases amongst others, regulate the progression of the cell through mitosis. So far three Aurora kinases have been identified in man: Aurora-A, Aurora-B and Aurora-C. Aurora kinases were recently identified as a potential target in anticancer therapy, and various Aurora-A and Aurora-B kinase inhibitors are in development. In this review we provide a brief insight into the mechanism of action as far as currently available. We review the available pre-clinical data, discuss the clinical phase I data and try to give a direction for future headings. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

AB - Most human cancer cells are characterized by changes in the amount or organization of DNA resulting in chromosome instability and aneuploidy. Several mitotic kinases, Aurora kinases amongst others, regulate the progression of the cell through mitosis. So far three Aurora kinases have been identified in man: Aurora-A, Aurora-B and Aurora-C. Aurora kinases were recently identified as a potential target in anticancer therapy, and various Aurora-A and Aurora-B kinase inhibitors are in development. In this review we provide a brief insight into the mechanism of action as far as currently available. We review the available pre-clinical data, discuss the clinical phase I data and try to give a direction for future headings. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

U2 - 10.1016/j.critrevonc.2009.03.009

DO - 10.1016/j.critrevonc.2009.03.009

M3 - Article

C2 - 19369091

SN - 1040-8428

VL - 73

SP - 99

EP - 110

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 2

ER -